WEST PHARMACEUTICAL SERVICES INC
WSTHealthcare
Latest available resultsSeptember 30, 2026Quarter · 10-Q filed Oct 29, 2026
Next reportFebruary 10, 2027after close · forecast 2.308 $/share
Revenue
$874.50M
▲ +8.7% vs prior year YoY
Net income
$214.00M
▲ +52.9% vs prior year YoY
EPS
3.02$
▲ +57.3% vs prior year YoY
Net margin
24.5%
▲ +7.1 pp vs prior year YoY
Revenue▲ +8.7%
Margins (% of revenue)GrossOperatingNet
Net income▲ +52.9%
EPS▲ +57.3%
Financial statements
View 10-Q filed October 29, 2026 on SEC ↗| Metric | Dec 2024* | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025* | Mar 2026 | Jun 2026 | Sep 2026 | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Operations | |||||||||
| Revenue | $748.80M | $698.00M | $766.50M | $804.60M | $805.00M | $844.90M | $872.30M | $874.50M | ▲ +8.7% |
| Gross profit | $273.60M | $231.90M | $273.90M | $294.30M | $303.90M | $296.40M | $329.20M | $347.40M | ▲ +18.0% |
| Operating income | $159.60M | $107.00M | $153.70M | $167.60M | $156.60M | $177.10M | $179.10M | $267.40M | ▲ +59.5% |
| Net income | $130.10M | $89.80M | $131.80M | $140.00M | $132.10M | $138.80M | $154.00M | $214.00M | ▲ +52.9% |
| R&D | $18.50M | $16.30M | $19.10M | $17.10M | $21.80M | $15.80M | $19.70M | $18.30M | ▲ +7.0% |
| EPS (diluted) | — | 1.23 $ | 1.82 $ | 1.92 $ | — | 1.92 $ | 2.15 $ | 3.02 $ | ▲ +57.3% |
| Margins (% of revenue) | |||||||||
| Gross | 36.5 % | 33.2 % | 35.7 % | 36.6 % | 37.8 % | 35.1 % | 37.7 % | 39.7 % | ▲ +3.1 pt |
| Operating | 21.3 % | 15.3 % | 20.1 % | 20.8 % | 19.5 % | 21.0 % | 20.5 % | 30.6 % | ▲ +9.7 pt |
| Net | 17.4 % | 12.9 % | 17.2 % | 17.4 % | 16.4 % | 16.4 % | 17.7 % | 24.5 % | ▲ +7.1 pt |
| Balance sheet | |||||||||
| Assets | $3.64B | $3.62B | $3.95B | $4.11B | $4.27B | $4.11B | $4.08B | $4.06B | ▼ -1.1% |
| Liabilities | $961.10M | $935.10M | $1.02B | $1.05B | $1.09B | $1.12B | $1.09B | $1.09B | ▲ +3.6% |
| Equity | $2.68B | $2.68B | $2.93B | $3.05B | $3.18B | $2.99B | $2.99B | $2.97B | ▼ -2.7% |
| Cash | $484.60M | $404.20M | $509.70M | $628.50M | $791.30M | $521.40M | $435.80M | $464.10M | ▼ -26.2% |
| Capital | |||||||||
| Shares outstanding | 72.30M | 71.85M | 71.91M | 71.94M | 72.02M | 70.65M | 70.38M | 69.66M | ▼ -3.2% |
| Public floatexcluding insiders | — | — | — | — | — | — | — | — | — |
* No 10-Q is filed for a fourth quarter: these amounts are the fiscal year minus the first three quarters, all filed. EPS stays blank — dilution doesn't subtract.